The major methyltransferases are: COMT (catechol-O-methyltransferase) : inactivates catecholamines (dopamine, norepinephrine, epinephrine), catechol estrogens, and catechol drugs (L-DOPA) R HNMT (histamine N-methyltransferase) : the primary intracellular histamine degradation enzyme in the brain and peripheral tissues R INMT (indolethylamine N-methyltransferase) : methylates tryptamine, serotonin, and other indoleamines R NNMT (nicotinamide N-methyltransferase) : methylates nicotinamide (vitamin B3) and other pyridines R TMT (thiol S-methyltransferase) : S-methylates thiol drugs (captopril, D-penicillamine) and thiol metabolites R TPMT (thiopurine S-methyltransferase) : methylates thiopurine drugs (azathioprine, 6-mercaptopurine) used in autoimmune disease and cancer R Methylation capacity depends on the methylation cycle: methionine to SAM-e to SAH to homocysteine, recycled back to methionine by methionine synthase (B12-dependent) or BHMT (betaine-dependent)
Research has examined its role in: GHRH receptor binding, Gs/adenylate cyclase activation, and cAMP/PKA signalling pathway studies Physiological pulsatile GH secretion modelling and somatotroph biology investigations GH and IGF-1 axis regulation and downstream anabolic signalling research DPP-4 resistance profiling and GHRH analogue structural pharmacology studies Somatotroph proliferation, GH mRNA transcription, and pituitary reserve research GH pulsatility architecture pulse amplitude, frequency, trough levels, and inter-pulse intervals Somatostatin feedback dynamics and GHRH/somatostatin interplay modelling Metabolic pathway research lipid oxidation, glucose homeostasis, and anabolic signalling GH axis ageing, somatopause, and GHRH pulse amplitude decline studies Dual-pathway synergy research when combined with GHS-R1a agonists such as Ipamorelin Comparative GHRH analogue pharmacology Sermorelin, Tesamorelin, and CJC-1295 DAC CJC-1295 Without DAC and Pituitary Somatotroph Biology Research in GHRH knockout mice using the CJC-1295 backbone demonstrated that administration caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred as confirmed by immunohistochemistry establishing that the tetrasubstituted GHRH scaffold acts not only on acute GH release but also on transcriptional upregulation of GH gene expression and pituitary somatotroph reserve, findings directly relevant to the no-DAC variants receptor biology
Pharmacological Class: Dual GIP and GLP-1 Receptor Agonist Tirzepatide belongs to a novel class of dual incretin receptor agonists
70% of the genes that get turned on too much that lead to this type of colon cancer get turned down secondary to GHK treatment and therapies
